WINTON GROUP Ltd Invests $3.23 Million in Edwards Lifesciences Co. (NYSE:EW)

WINTON GROUP Ltd purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 43,627 shares of the medical research company’s stock, valued at approximately $3,230,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in shares of Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the last quarter. Jennison Associates LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth about $555,939,000. Vanguard Group Inc. increased its position in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $213,844,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,553 shares of company stock worth $4,513,064. 1.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Stock Performance

Shares of EW opened at $71.17 on Friday. The firm’s 50 day moving average price is $71.47 and its two-hundred day moving average price is $70.46. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market cap of $41.84 billion, a P/E ratio of 10.21, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.